• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

    18.24 -0.41 (-2.20%)
    Streaming Delayed Price Updated: 2:16 PM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,052,342
    Open 18.65
    Bid (Size) 18.22 (300)
    Ask (Size) 18.26 (100)
    Prev. Close 18.65
    Today's Range 18.10 - 18.82
    52wk Range 6.550 - 20.22
    Shares Outstanding 60,069,512
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
    This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 ↗
    Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming... 
    Via MarketBeat

    Performance

    YTD
    +53.4%
    +53.4%
    1 Month
    +1.6%
    +1.6%
    3 Month
    +27.9%
    +27.9%
    6 Month
    +59.3%
    +59.3%
    1 Year
    +146.2%
    +146.2%

    More News

    Read More
    News headline image
    As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
    Via The Motley Fool
    Trevi Therapeutics Inc. (NASDAQ:TRVI) Beats Q4 2025 EPS Estimates, Gains FDA Alignment for Phase 3 Program ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 13, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For May 8, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Preview For Trevi Therapeutics ↗
    Via Benzinga
    News headline image
    Trevi Therapeutics (TRVI) Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns ↗
    Via Stocktwits
    News headline image
    MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
    Via MarketBeat
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans ↗
    Via Chartmill
    News headline image
    A Peek at Trevi Therapeutics's Future Earnings ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    Via Benzinga
    News headline image
    This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    Dow Gains Over 100 Points; US Job Openings Increase In April ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients ↗
    Via Benzinga
    News headline image
    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
    From Avalo Therapeutics
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For March 18, 2025 ↗
    Via Benzinga

    Frequently Asked Questions

    Is Trevi Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Trevi Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Trevi Therapeutics, Inc. - Common Stock trade on?
    Trevi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Trevi Therapeutics, Inc. - Common Stock?
    The ticker symbol for Trevi Therapeutics, Inc. - Common Stock is TRVI on the Nasdaq Stock Market
    What is the current price of Trevi Therapeutics, Inc. - Common Stock?
    The current price of Trevi Therapeutics, Inc. - Common Stock is 18.24
    When was Trevi Therapeutics, Inc. - Common Stock last traded?
    The last trade of Trevi Therapeutics, Inc. - Common Stock was at 08/06/26 02:16 PM ET
    What is the market capitalization of Trevi Therapeutics, Inc. - Common Stock?
    The market capitalization of Trevi Therapeutics, Inc. - Common Stock is 1.10B
    How many shares of Trevi Therapeutics, Inc. - Common Stock are outstanding?
    Trevi Therapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.